Evotec SE Reports H1 2025 Results Highlighting Strategic Progress

Evotec SE has announced its financial results for the first half of 2025, showcasing advancements in its strategic execution aimed at sustainable and profitable growth. The company has reported group revenues of €371.2 million, marking a 5% decline compared to the previous year. The Discovery & Preclinical Development (D&PD) segment saw an 11% decrease due to a soft drug discovery market, whereas Just – Evotec Biologics (JEB) experienced a 16% increase in revenue, surpassing expectations with an expanded customer base.

Notably, Evotec's collaboration with Bristol Myers Squibb (BMS) on targeted protein degradation and neuroscience made significant progress, resulting in performance-based payments totaling US$ 95 million. Additionally, the company announced a potential sale of its J.POD biologics manufacturing facility in Toulouse for US$ 300 million in cash, as part of transitioning JEB to a more scalable model.

Evotec maintains a strong outlook for the remainder of 2025, with projected revenues ranging from €760 to €800 million and an adjusted Group EBITDA target of €30 to €50 million.